GlassScriptPhysician profile
Samantha Wild
NPI 1750734265
$5,827.83
in general payments reported to CMS, 2019-2025
28 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,015 · 2022: $890 · 2023: $1,123 · 2024: $1,540 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,844 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,843.53 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,292.08 | 2021-2025 | Nucala, Benlysta |
| Astrazeneca Pharmaceuticals LP | $754.05 | 2021-2025 | Saphnelo, Fasenra |
| Daiichi Sankyo INC. | $476.25 | 2021-2025 | Injectafer |
| Lilly USA, LLC | $430.42 | 2023-2025 | Omvoh, Kisunla |
| Amgen INC. | $329.87 | 2021-2024 | Evenity, Uplizna, Prolia |
| Lundbeck LLC | $328.44 | 2021-2025 | Vyepti |
| Pharmacosmos Therapeutics INC. | $301.06 | 2023-2025 | Monoferric, Cosela |
| Janssen Biotech, INC. | $253.65 | 2024-2025 | Tremfya |
| Abbvie INC. | $240.95 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $238.94 | 2021-2022 | |
| Tg Therapeutics, INC. | $217.48 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.54 | 2023-2024 | Hyqvia |
| Grifols USA, LLC | $106.12 | 2025 | Xembify, Gamunex-C |
| Argenx US, INC. | $99.37 | 2023 | Vyvgart |
| Adma Biomanufacturing LLC | $90.76 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $89.58 | 2021 | |
| Genentech USA, INC. | $74.06 | 2022-2024 | Ocrevus |
| Biogen, INC. | $69.23 | 2022-2025 | Leqembi |
| Merck Sharp & Dohme LLC | $65.96 | 2024 | Zerbaxa, Recarbrio |
| Tersera Therapeutics LLC | $55.79 | 2022-2023 | Quzyttir |
| Eisai INC. | $41.97 | 2024-2025 | |
| Horizon Therapeutics Plc | $35.23 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $34.71 | 2021-2024 | Simlandi |
| Sandoz INC. | $22.29 | 2025 | Tyruko |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.89 | 2024 | Spevigo |
| Melinta Therapeutics, LLC | $20.34 | 2021 | |
| Ethicon US, LLC | $14.72 | 2021 | |
| Csl Behring | $13.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Wild listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.